Skip to main content

Avalo Therapeutics, Inc.

corporate_fare Company Profile

Avalo Therapeutics, Inc.

AVTX·NASDAQ·Life Sciences·CIK 0001534120

The company is a clinical stage biotechnology company focused on developing treatments for immune-mediated inflammatory diseases using IL-1β-based therapies. Its primary product candidate is abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody. Abdakibart (AVTX-009) is currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS), known as the LOTUS trial. The company aims to complete this Phase 2 trial and prepare for anticipated topline data readout in the second quarter of 2026, followed by planning for Phase 3 trials. The company's strategy includes advancing its pipeline through development to regulatory approval, with a near-term focus on the Phase 2 LOTUS trial in HS and preparing to initiate pivotal trials. It also seeks to acquire or in-license rights to and/or develop targeted, complementary preclinical and clinical stage compounds for immune-mediated inflammatory diseases. Additionally, the company may opportunistically out-license rights to compounds, indications, or geographies. Abdabibart (AVTX-009) is a high affinity, highly potent humanized IgG4 monoclonal antibody designed to specifically inhibit IL-1β and block downstream inflammatory pathways. IL-1β is a pro-inflammatory cytokine central to many human diseases, activating immune cells that produce other pro-inflammatory cytokines like IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling drives inflammation and contributes to autoimmune disorders, and IL-1β inhibition has shown effectiveness in various immune-mediated inflammatory diseases.

Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AVTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Two Directors Depart Avalo Therapeutics Board Amidst Financial Challenges
  • Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
  • Avalo Therapeutics Reports 2025 Financials, Extends Cash Runway into 2028, and Anticipates Key Phase 2 Data in Q2 2026
  • Officer Files Intent to Sell $466K in Shares Following Option Exercise
  • Avalo Therapeutics Discloses $98M Cash, Extending Runway into 2028

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$59K
Net Income
-$78.26M
Diluted EPS
-$5.84
Op. Cash Flow
-$51.46M
Operating Income
-$72.92M
Cash & Equivalents
$15.86M
Debt / Equity
0.00×
Net Margin
-1326.42×
Shares Outstanding
18.51M sh
Source: 10-K · filed 2026-03-23 · accession 0001534120-26-000011
$6.76
52-week range · as of 2026-11-05 $6.53 – $24.27
Market cap
$390.88M
Volume
1.2M (0.4× avg)
3-mo avg 2.7M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed AVTX - Filings & News (Page 2)

AVTX
Mar 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.89
Real-time Price: $6.76 info
Change: -$7.13 (-51%) info
Market Cap: $390.884M info
AVTX
Mar 23, 2026, 7:02 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $13.40
Real-time Price: $6.76 info
Change: -$6.64 (-50%) info
Market Cap: $390.884M info
AVTX
Mar 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $13.40
Real-time Price: $6.76 info
Change: -$6.64 (-50%) info
Market Cap: $390.884M info
AVTX
Mar 16, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $16.02
Real-time Price: $6.76 info
Change: -$9.26 (-58%) info
Market Cap: $390.884M info
AVTX
Jan 12, 2026, 7:53 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $16.95
Real-time Price: $6.76 info
Change: -$10.19 (-60%) info
Market Cap: $390.884M info
AVTX
Jan 08, 2026, 4:01 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $17.11
Real-time Price: $6.76 info
Change: -$10.35 (-60%) info
Market Cap: $390.884M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets